CD274 and non-small cell lung carcinoma: Several studies have shown that increasing PD‐L1 expression is predictive of longer progression‐free survival (PFS) and overall survival (OS) after PD‐1 inhibition when compared to chemotherapy in stage IV NSCLC patients, and a cut‐off of 50% is used to select patients for first‐line monotherapy with pembrolizumab.11